1. Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol
- Author
-
Stephen Weng, Wallis C.Y. Lau, Esther W. Chan, Kenneth K.C. Man, Ralph K. Akyea, Kebede Beyene, Amy Hy Chan, Jeff Harrison, Annelize Coetzee, Ian C. K. Wong, and Joseph E Blais
- Subjects
medicine.medical_specialty ,Statin ,medicine.drug_class ,hydroxymethylglutaryl-coa reductase inhibitors ,primary prevention ,Disease ,030204 cardiovascular system & hematology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,cohort studies ,Internal medicine ,Medicine ,030212 general & internal medicine ,cardiovascular diseases ,lcsh:R5-920 ,business.industry ,Cholesterol ,Research ,cholesterol ,Guideline ,medicine.disease ,major adverse cardiovascular events ,chemistry ,Heart failure ,lipids (amino acids, peptides, and proteins) ,lcsh:Medicine (General) ,Family Practice ,business ,Mace ,Cohort study ,Kidney disease - Abstract
BackgroundClinical guidelines recommend specific targets for low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) for primary prevention of cardiovascular disease (CVD). Furthermore, individual variability in lipid response to statin therapy requires assessment of the association in diverse populations.AimTo assess whether lower concentrations of LDL-C and non-HDL-C are associated with a reduced risk of major adverse cardiovascular events (MACE) in primary prevention of CVD.Design & settingAn international, new-user, cohort study will be undertaken. It will use data from three electronic health record databases from three global regions: Clinical Practice Research Datalink, UK; PREDICT-CVD, New Zealand (NZ); and the Clinical Data and Analysis Reporting System, Hong Kong (HK).MethodNew statin users without a history of atherosclerotic CVD, heart failure, or chronic kidney disease, with baseline and follow-up lipid levels will be eligible for inclusion. Patients will be classified according to LDL-C (ConclusionResults will inform clinicians about the benefits of achieving guideline recommended concentrations of LDL-C for primary prevention of CVD.
- Published
- 2021